Jedličková L, Dvorak J, Hrachovinova I, Ulrychová L, Kasný M, Mikes L. A novel Kunitz protein with proposed dual function from Eudiplozoon nipponicum (Monogenea) impairs haemostasis and action of complement in vitro. Int J Parasitol. 2019;: pubmed publisher

Porras G, Ayuso M, González Manchón C. Leukocyte-endothelial cell interaction is enhanced in podocalyxin-deficient mice. Int J Biochem Cell Biol. 2018;99:72-79 pubmed publisher

Lauw M, Coppens M, Eikelboom J. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. Can J Cardiol. 2014;30:381-4 pubmed publisher

Louis S, Van P, Riha G, Barton J, Kunio N, Underwood S, et al. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. J Trauma Acute Care Surg. 2014;76:937-42; discussion 942-3 pubmed publisher

Bruins Slot K, Berge E. Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. JAMA. 2014;311:1150-1 pubmed publisher

Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol. 2014;113:1362-3 pubmed publisher

Cohen A, Harrington R, Goldhaber S, Hull R, Gibson C, Hernandez A, et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014;167:335-41 pubmed publisher

Xu Y, Cai C, Chandarajoti K, Hsieh P, Li L, Pham T, et al. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nat Chem Biol. 2014;10:248-50 pubmed publisher

Ice D, Shapiro T, Gnall E, Kowey P. Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. Am J Cardiol. 2014;113:888-96 pubmed publisher

Erkan D, Aguiar C, Andrade D, Cohen H, Cuadrado M, Danowski A, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685-96 pubmed publisher

Srivasatava K, Majumder R, Kane W, Quinn Allen M, Lentz B. Phosphatidylserine and FVa regulate FXa structure. Biochem J. 2014;459:229-39 pubmed publisher

Raja A, Geyer B. Emergency department management of patients on novel oral anticoagulant agents. Emerg Med Pract. 2013;15:1-18; quiz 18-9 pubmed

Droege M, Mueller E, Besl K, Lemmink J, Krämer E, Athota K, et al. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2014;76:450-6 pubmed publisher

Lakkireddy D, Reddy Y, Di Biase L, Vallakati A, Mansour M, Santangeli P, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63:982-8 pubmed publisher

Quan M, Wong P, Wang C, Woerner F, Smallheer J, Barbera F, et al. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem. 2014;57:955-69 pubmed publisher

Simeon L, Nagler M, Wuillemin W. [New oral anticoagulants - influence on coagulation tests]. Dtsch Med Wochenschr. 2014;139:94-9 pubmed publisher

Diez Ewald M. [From apixaban to aspirin in the prevention of recurrent venous thromboembolism]. Invest Clin. 2013;54:231-3 pubmed

Goodman S, Wojdyla D, Piccini J, White H, Paolini J, Nessel C, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891-900 pubmed publisher

Bastiaans J, van Meurs J, van Holten Neelen C, Nagtzaam N, van Hagen P, Chambers R, et al. Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling. Invest Ophthalmol Vis Sci. 2013;54:8306-14 pubmed publisher

Völler H. [New options in the treatment of atrial fibrillation]. Dtsch Med Wochenschr. 2013;138:2579 pubmed publisher

Sprynger M. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism]. Rev Med Liege. 2013;68:548-51 pubmed

Kopelman T, O Neill P, Pieri P, Salomone J, Hall S, Quan A, et al. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?. Am J Surg. 2013;206:911-5; discussion 915-6 pubmed publisher

. [Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice]. MMW Fortschr Med. 2013;155:62-3 pubmed

Dockal M, Hartmann R, Fries M, Thomassen M, Heinzmann A, Ehrlich H, et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem. 2014;289:1732-41 pubmed publisher

Wood J, Ellery P, Maroney S, Mast A. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2014;34:169-76 pubmed publisher

. [Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy]. MMW Fortschr Med. 2013;155:56-7 pubmed

Rodgers R, Bagot C, Lawrence C, Hickman G, McGurk M, Tait R. Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol. 2013;163:685-7 pubmed publisher

Bauer K. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38-40 pubmed publisher

Alameddine R, Husari A. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:1944-5 pubmed publisher

Cohen A, Spiro T, Spyropoulos A. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:1945-6 pubmed publisher

Ansell J. Blocking bleeding: reversing anticoagulant therapy. Nat Med. 2013;19:402-4 pubmed publisher

King C, Holley A, Moores L. Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. Chest. 2013;143:1106-1116 pubmed publisher

Vandiver J, Vondracek T. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Hosp Pract (1995). 2013;41:16-24 pubmed publisher

Yang L, Rezaie A. Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa. J Biol Chem. 2013;288:12692-8 pubmed publisher

Mega J, Braunwald E, Murphy S, Plotnikov A, Burton P, Kiss R, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome. J Am Coll Cardiol. 2013;61:1853-9 pubmed publisher

Fritsma G. Monitoring the anti-Xa anticoagulants, from heparin to eliquis. Clin Lab Sci. 2013;26:48-53 pubmed

Dolgin E. Antidotes edge closer to reversing effects of new blood thinners. Nat Med. 2013;19:251 pubmed publisher

Galanis T, Merli G. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation. Hosp Pract (1995). 2013;41:26-36 pubmed publisher

Lu G, Deguzman F, Hollenbach S, Karbarz M, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-51 pubmed publisher

Dyrkorn R, Roland P. [New anticoagulants--should we have a little bit of cold water in the blood?]. Tidsskr Nor Laegeforen. 2013;133:390-1 pubmed publisher

Patel M, Hellkamp A, Lokhnygina Y, Piccini J, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevent. J Am Coll Cardiol. 2013;61:651-8 pubmed publisher

Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-23 pubmed publisher

. Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther. 2013;55:9-10 pubmed

. [Xarelto: other advantages]. Perspect Infirm. 2013;10:59 pubmed

Amin A. Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging. 2013;8:75-84 pubmed publisher

Strain J, Templeton K. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?. S D Med. 2013;66:20-1 pubmed

Reikvam A. [Is the warfarin era over?]. Tidsskr Nor Laegeforen. 2012;132:2583 pubmed publisher

Somjen D, Katzburg S, Gigi R, Dolkart O, Sharon O, Salai M, et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013;135:67-70 pubmed publisher

Thomas T, Ganetsky V, Spinler S. Rivaroxaban: an oral factor Xa inhibitor. Clin Ther. 2013;35:4-27 pubmed publisher

Stavik B, Tinholt M, Sletten M, Skretting G, Sandset P, Iversen N. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. J Hematol Oncol. 2013;6:5 pubmed publisher

Warner R, McClintock S, Barron A, de la Iglesia F. Hemostatic properties of a venomic protein in rat organ trauma. Exp Mol Pathol. 2009;87:204-11 pubmed publisher

Jackson C, Nemerson Y. Blood coagulation. Annu Rev Biochem. 1980;49:765-811 pubmed

McMullen B, Fujikawa K, Kisiel W, Sasagawa T, Howald W, Kwa E, et al. Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid. Biochemistry. 1983;22:2875-84 pubmed

Cho K, Tanaka T, Cook R, Kisiel W, Fujikawa K, Kurachi K, et al. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. Biochemistry. 1984;23:644-50 pubmed

Jesty J, Nemerson Y. The activation of bovine coagulation factor X. Methods Enzymol. 1976;45:95-107 pubmed

Fujikawa K, Davie E. Bovine factor X (Stuart factor). Methods Enzymol. 1976;45:89-95 pubmed